290 related articles for article (PubMed ID: 23490655)
1. Ten-year analysis of the prospective multicentre Chemo-N0 trial validates American Society of Clinical Oncology (ASCO)-recommended biomarkers uPA and PAI-1 for therapy decision making in node-negative breast cancer patients.
Harbeck N; Schmitt M; Meisner C; Friedel C; Untch M; Schmidt M; Sweep CG; Lisboa BW; Lux MP; Beck T; Hasmüller S; Kiechle M; Jänicke F; Thomssen C;
Eur J Cancer; 2013 May; 49(8):1825-35. PubMed ID: 23490655
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant chemotherapy in node-negative breast cancer: UPA/PAI-1 determinations for 163 cases.
Vénat-Bouvet L; Fermeaux V; Leobon S; Saidi N; Monteil J; Mollard J; Aubard Y; Jammet I; Tubiana-Mathieu N
Anticancer Res; 2014 Mar; 34(3):1213-7. PubMed ID: 24596362
[TBL] [Abstract][Full Text] [Related]
3. Prospective evaluation of prognostic factors uPA/PAI-1 in node-negative breast cancer: phase III NNBC3-Europe trial (AGO, GBG, EORTC-PBG) comparing 6×FEC versus 3×FEC/3×Docetaxel.
Kantelhardt EJ; Vetter M; Schmidt M; Veyret C; Augustin D; Hanf V; Meisner C; Paepke D; Schmitt M; Sweep F; von Minckwitz G; Martin PM; Jaenicke F; Thomssen C; Harbeck N
BMC Cancer; 2011 Apr; 11():140. PubMed ID: 21496284
[TBL] [Abstract][Full Text] [Related]
4. Impact of guideline-based use of uPA/PAI-1 on patient outcome in intermediate-risk early breast cancer.
Kolben T; Augustin D; Armbrust R; Kolben TM; Degenhardt T; Burgmann M; Goess C; Ditsch N; Kates R; Harbeck N; Wuerstlein R
Breast Cancer Res Treat; 2016 Jan; 155(1):109-15. PubMed ID: 26643086
[TBL] [Abstract][Full Text] [Related]
5. Prognostic impact of the inclusion of uPA/PAI-1 tumor levels in the current adjuvant treatment decision-making for early breast cancer.
Saadoun H; Lamy PJ; Thezenas S; Pouderoux S; Bibeau F; Montels F; Romieu G; Colombo PE; Gutowski M; Jacot W
Future Oncol; 2014 Feb; 10(2):195-209. PubMed ID: 24490606
[TBL] [Abstract][Full Text] [Related]
6. Identification of patients with node-negative, triple-negative breast cancer who benefit from adjuvant cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy.
Wu CE; Chen SC; Lin YC; Lo YF; Hsueh S; Chang HK
Anticancer Res; 2014 Mar; 34(3):1301-6. PubMed ID: 24596377
[TBL] [Abstract][Full Text] [Related]
7. Prospective multi-center study for quantification of chemotherapies and CTX-related direct medication costs avoided by use of biomarkers uPA and PAI-1 in primary breast cancer.
Jacobs VR; Augustin D; Wischnik A; Kiechle M; Höss C; Steinkohl O; Rack B; Kapitza T; Krase P
Breast; 2013 Aug; 22(4):436-43. PubMed ID: 23643802
[TBL] [Abstract][Full Text] [Related]
8. Prognostic impact of the inclusion of uPA/PAI-1 for adjuvant treatment decision-making in ER+/Her2- pN0 early breast cancers.
Viala M; Alexandre M; Thezenas S; Lamy PJ; Maran-Gonzalez A; Gutowski M; Colombo PE; Romieu G; Jacot W; Guiu S
Breast Cancer Res Treat; 2017 Oct; 165(3):611-621. PubMed ID: 28685212
[TBL] [Abstract][Full Text] [Related]
9. Urokinase plasminogen activator and its inhibitor type-1 as prognostic factors in differentiated thyroid carcinoma patients.
Horvatic Herceg G; Herceg D; Kralik M; Kulic A; Bence-Zigman Z; Tomic-Brzac H; Bracic I; Kusacic-Kuna S; Prgomet D
Otolaryngol Head Neck Surg; 2013 Oct; 149(4):533-40. PubMed ID: 23835563
[TBL] [Abstract][Full Text] [Related]
10. uPA and PAI-1 as biomarkers in breast cancer: validated for clinical use in level-of-evidence-1 studies.
Duffy MJ; McGowan PM; Harbeck N; Thomssen C; Schmitt M
Breast Cancer Res; 2014 Aug; 16(4):428. PubMed ID: 25677449
[TBL] [Abstract][Full Text] [Related]
11. Decision impact and feasibility of different ASCO-recommended biomarkers in early breast cancer: Prospective comparison of molecular marker EndoPredict and protein marker uPA/PAI-1.
Ettl J; Klein E; Hapfelmeier A; Grosse Lackmann K; Paepke S; Petry C; Specht K; Wolff L; Höfler H; Kiechle M
PLoS One; 2017; 12(9):e0183917. PubMed ID: 28877230
[TBL] [Abstract][Full Text] [Related]
12. European cost-effectiveness study of uPA/PAI-1 biomarkers to guide adjuvant chemotherapy decisions in breast cancer.
Marguet S; Mazouni C; Ramaekers BL; Dunant A; Kates R; Jacobs VR; Joore MA; Harbeck N; Bonastre J
Eur J Cancer; 2016 Aug; 63():168-79. PubMed ID: 27322916
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial.
Coleman R; Cameron D; Dodwell D; Bell R; Wilson C; Rathbone E; Keane M; Gil M; Burkinshaw R; Grieve R; Barrett-Lee P; Ritchie D; Liversedge V; Hinsley S; Marshall H;
Lancet Oncol; 2014 Aug; 15(9):997-1006. PubMed ID: 25035292
[TBL] [Abstract][Full Text] [Related]
14. Markers of progression and invasion in short term follow up of untreated breast cancer patients.
Rabi ZA; Todorović-Raković N; Vujasinović T; Milovanović J; Nikolić-Vukosavljević D
Cancer Biomark; 2015; 15(6):745-54. PubMed ID: 26406416
[TBL] [Abstract][Full Text] [Related]
15. Concordance rates of biomarkers uPA and PAI-1 results in primary breast cancer vs. consecutive tumor board decision and therapy performed in clinical hospital routine: Results of a prospective multi-center study at certified breast centers.
Jacobs VR; Augustin D; Wischnik A; Kiechle M; Hoess C; Steinkohl O; Rack B; Kapitza T; Krase P
Breast; 2016 Oct; 29():208-12. PubMed ID: 27344290
[TBL] [Abstract][Full Text] [Related]
16. Association of uPA and PAI-1 tumor levels and 4G/5G variants of PAI-1 gene with disease outcome in luminal HER2-negative node-negative breast cancer patients treated with adjuvant endocrine therapy.
Jevrić M; Matić IZ; Krivokuća A; Đorđić Crnogorac M; Besu I; Damjanović A; Branković-Magić M; Milovanović Z; Gavrilović D; Susnjar S; Kisić Tepavčević D; Stanojković T
BMC Cancer; 2019 Jan; 19(1):71. PubMed ID: 30646864
[TBL] [Abstract][Full Text] [Related]
17. [uPA/PAI-1, Oncotype DX™, MammaPrint(®). Prognosis and predictive values for clinical utility in breast cancer management].
Bellocq JP; Luporsi E; Barrière J; Bonastre J; Chetritt J; Le Corroller AG; de Crémoux P; Fina F; Gauchez AS; Kassab-Chahmi D; Lamy PJ; Martin PM; Mazouni C; Peyrat JP; Romieu G; Verdoni L; Mazeau-Woynar V
Ann Pathol; 2014 Oct; 34(5):349-51. PubMed ID: 25439987
[TBL] [Abstract][Full Text] [Related]
18. Potential clinical relevance of uPA and PAI-1 levels in node-negative, postmenopausal breast cancer patients bearing histological grade II tumors with ER/PR expression, during an early follow-up.
Buta M; Džodić R; Đurišić I; Marković I; Vujasinović T; Markićević M; Nikolić-Vukosavljević D
Tumour Biol; 2015 Sep; 36(10):8193-200. PubMed ID: 25994573
[TBL] [Abstract][Full Text] [Related]
19. Clinical significance of urokinase-type plasminogen activator (uPA) and its type-1 inhibitor (PAI-1) for metastatic sentinel lymph node involvement in breast cancer.
Harms W; Malter W; Krämer S; Drebber U; Drzezga A; Schmidt M
Anticancer Res; 2014 Aug; 34(8):4457-62. PubMed ID: 25075085
[TBL] [Abstract][Full Text] [Related]
20. Assessment of Ki67 and uPA/PAI-1 expression in intermediate-risk early stage breast cancers.
Deluche E; Venat-Bouvet L; Leobon S; Fermeaux V; Mollard J; Saidi N; Jammet I; Aubard Y; Tubiana-Mathieu N
BMC Cancer; 2017 Sep; 17(1):662. PubMed ID: 28954632
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
